Filter
Reset all

Subjects

Content Types

Countries

AID systems

API

Data access

Data access restrictions

Database access

Database access restrictions

Data licenses

Data upload

Data upload restrictions

Enhanced publication

Institution responsibility type

Institution type

Keywords

Metadata standards

PID systems

Provider types

Quality management

Repository languages

Software

Repository types

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 4 result(s)
MIDRC aims to develop a high-quality repository for medical images related to COVID-19 and associated clinical data, and develop and foster medical image-based artificial intelligence (AI) for use in the detection, diagnosis, prognosis, and monitoring of COVID-19.
VIPERdb is a database for icosahedral virus capsid structures . The emphasis of the resource is on providing data from structural and computational analyses on these systems, as well as high quality renderings for visual exploration. In addition, all virus capsids are placed in a single icosahedral orientation convention, facilitating comparison between different structures. The web site includes powerful search utilities , links to other relevant databases, background information on virus capsid structure, and useful database interface tools.
The Coronavirus Antiviral Research Database is designed to expedite the development of SARS-CoV-2 antiviral therapy. It will benefit global coronavirus drug development efforts by (1) promoting uniform reporting of experimental results to facilitate comparisons between different candidate antiviral compounds; (2) identifying gaps in coronavirus antiviral drug development research; (3) helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development; (4) providing an objective, evidenced-based, source of information for the public; and (5) creating a hub for the exchange of ideas among coronavirus researchers whose feedback is sought and welcomed. By comprehensively reviewing all published laboratory, animal model, and clinical data on potential coronavirus therapies, the Database makes it unlikely that promising treatment approaches will be overlooked. In addition, by making it possible to compare the underlying data associated with competing treatment strategies, stakeholders will be better positioned to prioritize the most promising anti-coronavirus compounds for further development.